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Abstract: Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are responsible for the deve-
lopment of metastatic disease, and may also hold the key to determining tailored therapies of advanced cancer 
disease. Our review summarizes the prognostic significance of the detection of CTCs and DTCs in various 
gastrointestinal cancers with an overview of their possible use as prognostic biomarkers. This could be used in 
the future as a starting point for new clinical trials focusing on the predictive potential of circulating and disse-
minated tumor cells. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 4, 265–277)
Key words: circulating tumor cells;  gastrointestinal cancer; esophageal cancer; colorectal cancer; gastric cancer; 
plastin3; prognosis
Abbreviations
AFP — alpha fetoprotein; BM — bone marrow; CD 
— cluster of differentiation; CEA — carcinoembry-
onic antigen; CHT — chemotherapy; CI — confiden-
ce interval; CTC — circulating tumor cell; CRC — 
colorectal carcinoma; CVB — central venous blood; 
CK — cytokeratin; DAPI — 4,6-diamidino-2-pheny-
lindole; DFS — disease free survival; DTC — dissemi-
nated tumor cell; EpCAM — epithelial cell adhesion 
molecule; FISH — fluorescent in situ hybridization; 
5-FU — 5-fluorouracil; HCC — hepatocellular carci-
noma; HR — hazard ratio; ISET — isolation by size of 
epithelial tumor; ITC — isolated tumor cells; MACS 
— magnetic activated cell sorting; MFS — metastasis 
free survival; MSP — methylation specific polymerase 
chain reaction; MVB — mesenteric venous blood; NA 
— not available; OS — overall survival; PB — peri-
pheral blood; PFS — progression-free survival; qPCR 
— quantitative real-time polymerase chain reaction; 
RFA — radiofrequency ablation; RT — radiotherapy; 
RT-PCR — reverse transcription polymerase chain 
reaction; TGFb1 — transforming growth factor b1; 
TRC method — transcription reverse-transcription 
concerted method 
Introduction
Single tumor cells occurring in blood circulation are 
called circulating tumor cells (CTCs), while the single 
tumor cells seeding distant organs prior to detection 
of metastasis are termed DTCs (disseminated tumor 
cells) [1]. CTCs and DTCs are believed to be respon-
sible for the development of metastatic disease, as 
shown in the parallel-progression model of metastatic 
cascade [1, 2].
Over the last decade, various methods and systems 
have been developed to isolate and characterize CTCs 
and DTCs. The presence of these cells accompanies 
tumor invasion through the bloodstream and dissemi-
nation into other distant sites. Much effort has been 
necessary to understand the biology of cancer disse-
mination and to make clinical use of CTCs and DTCs. 
Our review summarizes the prognostic significance of 
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the detection of circulating and disseminated tumor 
cells in various gastrointestinal cancers with a view of 
their future use in testing processes in clinical studies. 
A cancer cell in circulation: a rare event 
Recently, our understanding of cancer has conside-
rably improved. While the basic definition of cancer 
remains unchanged, it is now considered a complex 
disease. CTCs and DTCs may be rare events of pri-
mary tumor progression. Many clinical studies have 
been conducted showing the utility of CTC detection 
in the peripheral blood as a valuable predictor of the 
clinical outcome for patients with solid tumors [3–5]. 
Detection, monitoring, and molecular analysis of 
these extremely rare cancer cells (estimated as one 
tumor cell per billion normal blood cells in patients 
with diagnosed metastatic cancer) could provide new 
possibilities in cancer treatment [6].
The methodology used for CTCs studies in gastro-
intestinal cancer has been reviewed in depth by Negin 
et al. [6]. There is no doubt that the development of 
new more sensitive detection techniques is crucial, 
and is aimed at gaining higher counts of CTCs and 
DTCs to make these methods into powerful tools of 
prediction. We have tried to produce a useful overview 
of recent methods of detection, isolation, and charac-
terization of CTCs, such as immunomagnetic separa-
tion, flow cytometry, fluorescent in situ hybridization 
(FISH), and reverse transcription polymerase chain 
reaction (RT-PCR).
Nowadays, the only predictive marker used in co-
lorectal carcinoma (CRC) is the KRAS gene, tested 
by gene mutational analysis. It is believed that we are 
close to discovering other genes for predictive purpo-
ses. This can also be achieved using CTCs, but their 
counts seem currently to be insufficient for proper 
analysis. CTC counts in analyzed peripheral blood in 
gastrointestinal cancers (e.g., esophageal and gastric 
cancer), are low compared with other malignancies 
such as breast and prostate cancer. The absolute num-
bers in gastrointestinal cancers (such as metastatic 
colorectal cancer) are reported as 1–2 CTCs/7.5 mL of 
blood, while in metastatic prostate and breast cancer, 
counts are on the level of 3–5 and 6–7 CTCs/7.5 mL 
of blood, respectively [7–10]. It has been discussed 
that that liver could filter the blood coming in from 
the peritoneum, so CTCs may remain in the liver and 
occupy hepatic tissue, developing local metastasis [6]. 
This could be the reason that significantly higher rates 
of CTCs can be found analyzing mesenteric venous 
blood (MVB) in comparison to the peripheral blood 
[11]. This fact should be reflected in clinical studies, 
where perioperative blood sampling might be a source 
of CTCs for predictive analysis.
The range of possible diagnostic and therapeutic 
uses of CTCs is very wide. Firstly, monitoring cancer 
disease and demonstrating the therapeutic success 
achieved by molecular testing of CTCs (which in 
future may be known as ‘liquid biopsy’) are possible 
applications. Secondly, useful methods for inoperable 
patients where there is no other possibility of obta-
ining information about the tumor character (which 
could be called ‘real-time tumor biopsy’) is another 
option. In addition, it seems that CTCs and DTCs 
could provide a very good source of information about 
the chemosensitivity and chemoresistance of the pri-
mary tumor and about distant sites of metastasis [12].
However, very little is still known about the exact 
number of tumor cells released into the bloodstream by 
tumors in humans. It is hypothesized that 1 g of primary 
tumor may release 106 cells into the bloodstream every 
24 hours [13]. It has been shown in orthotopic meta-
static tumor animal models that surgical manipulation 
during oncological procedures may enhance the release 
of cancer cells from the primary tumor site into the 
circulation. Pressure, biopsy, and laser treatments can 
all dramatically increase CTC counts (up to sixty-fold), 
whereas proper tumor resection significantly decreases 
CTC count [14]. Similarly, increases in CTC counts 
have been show in human clinical studies of radiofrequ-
ency ablation (RFA) — a method of tissue destruction 
that uses the heat generated by high-frequency alter-
nating current. CTCs from patients with CRC liver 
metastases were quantified prior to and immediately 
after open surgery, laparoscopic resection, and open or 
percutaneous RFA. Surgical procedures led to a stati-
stically significant decrease in CTC counts measured 
at multiple sites (peripheral vein and artery, hepatic 
portal vein, hepatic vein). Conversely, RFA, whether 
open or percutaneous, was associated with a significant 
increase in CTC count [15]. It may be expected that in 
vivo detection of intervention-amplified CTCs could be 
used in the future for early diagnosis of small tumors 
undetectable with conventional methods [14].
Clinical impact of CTCs in clinical studies  
in patients with esophageal, gastric,  
and colorectal cancer 
The clinical relevance of CTC analysis in gastro-
intestinal cancers is summarized in Tables 1–4, in 
which studies are listed according to the diagnosis 
and the CTC detection method. Table 1 presents 
immunocytological analysis, whereas Table 2 shows 
RT-PCR analysis of CTCs in esophageal, gastric, 
and pancreatic cancers. Similarly, in Tables 3 and 
4, immunocytological and RT-PCR based studies of 
CTCs in colorectal carcinoma are presented. Some 
of the more interesting results are discussed below. 
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Table 1. CTCs/DTCs in esophageal and gastric cancer — immunocytological studies
Clinical 
Study
Year Pa-
tients 
(n)
Stage Sampling CTC DTC Diagnostic 
method 
OS (months)  P-value 
(OS)
Note
Vashist 
et al. [18]
2012 362 Mets, 
non
-mets
Pre- and 
post- 
operative
– Yes ICC, 
CK assay
DTCs– OS 39,9 
DTCs– DFS 
28,2  
DTCs+ OS 13,6 
DTCs+ DFS 
9,7 
P < 
0.001
Esophageal cancer, 
DTCs in bone marrow 
identified by CK 
(cytokeratin), 
detailed clinico- 
pathologic patient 
characteristic
Matsu-
saka et 
al. [28]
2010 52 Mets, 
non
-mets
At baseline, 
during  
therapy
Yes – Cell- 
Search® 
2 week point 
CTCs– OS 3,5 
CTCs– PFS 4,9 
CTCs+ OS 11,7 
CTCs+ PFS 1,4 
4 week point 
CTCs– OS 4,0 
CTCs– PFS 5,0 
CTCs+ 0S 11,4 
CTCs+ PFS 1,4
P ≤ 
0.001
Gastric cancer, 
detailed clinico- 
pathologic patient 
characteristic
Hiraiwa 
et al. [7]
2008 171 Mets, 
non
-mets
Pre- and 
post- 
operative
Yes – Cell- 
Search® 
NA  P = 
0.343 
(EC) 
P = 
0.032 
(GC)
Esophageal cancer 
(EC), gastric cancer 
(GC)
Kolo-
dziejczyk 
et al. [44]
2007 32 Mets, 
non
-mets
Before and 
after  
preoperative 
CHT
Yes Yes IF CTCs– 22,6 
CTCs+ 20,3
P = 
0.683
Gastric cancer 
effects of pre- 
operative CHT on 
CTCs/DTCs
CHT — chemotherapy; CK — cytokeratin; CTC — circulating tumor cell; DFS — disease-free survival; DTC — disseminated tumor cell; EC — 
esophageal cancer; GC — gastric cancer; ICC — immunocytochemistry; IF — immunofluorescence; Mets — metastases; NA — not available; OS 
— overall survival; PFS — progression-free survival
Table 2. CTCs/DTCs in esophageal and gastric cancers — gene expression based studies
Clinical 
Study
Year Pa-
tients 
(n)
Stage Sampling CTC DTC Dia-
gnostic 
method 
Mole-
cular 
markers 
OS 
(mon-
ths) 
 P-value 
(OS)
Note
Yin et al. 
[19]
2012 72 Mets, 
non
-mets
Pre- and 
post- 
radiotherapy
Yes – RT-PCR CK19, 
CEA, 
survivin
– NA CTC (+) post-radiothe-
rapy prognostic factor 
for ESCC apart from 
patients’ Karnofsky 
performance status 
scores.
de 
Albuqu-
erque et 
al. [45]
2012 247 Non
-mets
Pre- and 
post- 
operative
Yes – RT-PCR KRT19, 
MUC1, 
EPCAM, 
CE-
ACAM5, 
BIRCS, 
SCGB2A2, 
ERBB2
NA NA CTC (+) 66.7% in 
esophageal, 62.2% in 
gastric, 33.3% in small 
intestine, 60.6% in co-
lon, and 66.7% in rectal 
adenocarcinomas
Hoff-
mann et 
al. [46]
2009 59 NA Pre- and 
post- 
operative
Yes – Density 
gradient,  
RT-PCR
Methy-
lated 
DAPK 
or APC 
promoter
poor P = 0.04 –
Æ
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Table 2.  cd.
Braben-
der et al. 
[47]
2008 29 Non
-mets
Prior  
neoadjuvant 
CHT
Yes – Density 
gradient,  
RT-PCR
ERCC1 NA NA ERCC1 mRNA 
expression  
associated with 
response to  
neoadjuvant RT
Hoff-
mann  
et al. [48]
2007 62 NA Pre- and post- 
operative
Yes – Density 
gradient, 
RT-PCR
Survivn NA  P < 0.04 Survivin mRNA 
levels fall after 
surgical resection
Liu et al. 
[17]
2007 53 Non
-mets
Pre- and post- 
operative,  
3rd post-  
operative day
Yes – Density 
gradient, 
RT-PCR
CEA NA P < 0.05 Patients with high 
levels CEA in CTC 
fraction showed 
mets 1 year after 
surgery more often
Ikoma  
et al. [49]
2007 44 Mets, 
non
-mets
Preoperative Yes – RT-PCR, 
MSP
p16, E-
cadherin, 
RARbeta 
NA P = 0.05 Methylation- 
-specific PCR 
(MSP)
Hoff-
mann  
et al. [50]
2007 44 NA Postoperative Yes – Density 
gradient 
(On-
coQuick) 
RT-PCR
Survivin NA P < 0.04 Gastric, esophageal 
CRC, pancreatic: 
survivin levels fall 
after complete 
surgical resection
Ikeguchi 
et al. [51]
2005 59 NA Pre- and post- 
operative
Yes – RT-PCR CEA NA P = 0.064  Gastric cancer
Ito et al. 
[52]
2004 28 NA NA Yes – RT-PCR CEA, 
CK20
NA NA –
Kaganoi 
et al. [53]
2004 70 NA Pre-, intra- 
and post- 
operative
Yes – RT-PCR SCCA NA P < 0.001 Squamous cell 
carcinoma 
Antigen (SCCA) 
Huang  
et al. [54]
2003 62 NA Preoperative Yes – RT-PCR CEA, 
CK19, 
CK20 
NA NA Gastrointestinal 
cancer
Nakashi-
ma et al. 
[55]
2003 54 NA Preoperative Yes – RT-PCR CEA NA NA –
Koike  
et al. [56]
2002 33 Mets, 
non
-mets
Pre-, intra- 
and post- 
operative, 
1 week after  
surgery
Yes – RT-PCR Del-
taNp63
NA NA –
Miyazo-
no et al. 
[57]
2001 57 Mets, 
non
-mets
Pre- and post- 
operative
Yes – RT-PCR CEA NA NA Gastric cancer,  
surgical manipu-
lation
Soeth  
et al. [58]
1997 245 Mets, 
non
-mets
Preoperative Yes, 
104
Yes, 
141
RT-PCR CK20 for 
DTCs 
CK20 
RNA+ 
shorter 
OS
P > 0.0001 
(CRC) 
 P = 0.0414 
(GC), 
 NA (PC)
Gastric cancer 
(GC), colorectal 
cancer (CRC), 
pancreatic cancer 
(PC)
CHT, CK, CTC, DFS, DTC, GC, Mets, NA, OS – same as described for Table 1. BIRCs — BIR-containing proteins; CEA — carcinoembryonic 
antigen; CEACAM5 — carcinoembryonic antigen-related cell adhesion molecule 5; CRC — colorectal cancer; DAPK — death-associated protein 
kinase; ESCC — esophageal squamous cell carcinoma; EpCAM — epithelial cell adhesion molecule; ERBB2 — erythroblastic leukemia viral on-
cogene homolog 2; ERCC1 — excision repair cross-complementing 1 protein; MSP — methylation specific polymerase chain reaction; MUC1 — 
mucin 1; PC — pancreatic cancer; RT-PCR — reverse transcription polymerase chain reaction; SCGB2A2 — secretoglobin family 2A member 2.
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Esophageal cancer (EC)
Esophageal cancer (EC) is notorious for its aggressive 
biological behavior, local infiltration, involvement of 
adjacent lymph nodes, and broad metastasis through 
hematogenous spread. It has been reported that the 
frequency of hematogenous recurrence is high, despi-
te radical surgery with lymph node dissection [16]. In 
this regard, the detection of cancer cells in the blood 
could be important for identifying patients with a high 
risk of relapse. There have been many studies showing 
a positive correlation between detection of CTCs, 
tumor staging, and patient prognosis. Detection of 
CTCs from PB of EC patients by conventional qPCR 
methods has been reported for several genes.
Liu et al. [17] aimed at establishing a quantitative 
system for evaluating the role of CTCs in PB from 
patients who underwent surgical resection during 
esophageal cancer treatment. 155 PB samples from 
53 EC patients were collected before surgery (B-1), 
immediately after surgery (B0), and on the third po-
stoperative day (B+3). A direct qPCR method based 
on CEA mRNA gene expression was designed for the 
detection of CTCs. The authors showed significant 
differences between groups B-1 vs. B0 (p = 0.0001) 
and B-1 vs. B+3 (p = 0.0209). 50% of the patients 
with R > 0.4 (R = CTC ratio of B+3 over B0) showed 
tumor recurrence within 1 year after surgery, whereas 
the probability was only 14.3% for patients with R 
< 0.4 (p = 0.043). The prognostic utility of CTCs in 
EC has been shown also in studies where the gene 
expression of survivin, ERCC1, and APC has been 
tested by RT-PCR, as shown in Table 2.
The prognostic relevance of the presence of DTCs 
in bone marrow (BM) for the postoperative course of 
EC has also been evaluated recently [18]: 370 patients 
with EC diagnosis (189 squamous cell carcinomas and 
181 adenocarcinomas), were surgically treated with 
complete resection (R0). They received neither ad-
juvant nor neoadjuvant therapy. DTCs were detected 
by an immunocytochemical cytokeratin assay in pre-
operatively taken BM aspirates. Overall, 120 (32.4%) 
patients harbored DTCs in their BM. The presence 
of DTCs significantly correlated with aggressive 
tumor biology, as indicated by increased tumor size 
(p = 0.026), regional (p = 0.002) and distant 
(p = 0.012) lymph node metastases, and higher re-
lapse rate (p < 0.001, c2 test). The presence of DTCs 
in bone marrow was a very strong and independent 
prognostic factor in patients with resectable EC [18].
The CTC status in the PB of patients with eso-
phageal squamous cell carcinoma (ESCC), before 
and after radiotherapy (RT), was evaluated by Yin 
et al. [19]. A total of 72 ESCC patients enrolled in 
this study were treated with radical RT. The nested 
RT-PCR reaction was used to detect the three repre-
sentative markers of CTCs: CEA, CK19, and survivin. 
The results showed that the presence of CTCs, and 
the positive expression of at least one of these three 
markers in patients with ESCC pre-RT and post-RT 
were 54.2% and 38.9%, respectively (p = 0.059). 
Furthermore, the analysis of the patients according to 
lymph node metastasis and adverse 2-year progression
-free survival (PFS) revealed changes in CTC status 
after RT, which would reflect patients’ response to 
RT. In a multivariate analysis with the Cox propor-
tional hazard model, only CTC positivity post-RT 
was an independent, unfavorable prognostic factor 
for ESCC, apart from subsequent chemotherapy and 
patients’ Karnofsky performance status scores (a scale 
quantifying cancer patients’ general well-being). In 
conclusion, the positive detection of CTCs in patients 
with ESCC after RT may be a promising biomarker 
for radiation efficiency and prognosis assessment in 
ESCC [19].
Gastric cancer (GC) 
Follow-up studies on gastric cancer (GC) patients 
suggested that CTC-positive cases with increased bur-
dens of CTCs were associated with poorer prognoses 
than CTC-negative cases. The situation was similar 
with DTCs [15]. Both localized and metastatic GC 
can shed detectable concentrations of CTCs into the 
blood. The presence of CTCs in circulation suggests 
not only a high risk of tumor recurrence, but also an 
unfavorable clinical outcome even in the early stages 
of GC [20]. The prognostic impact of CTCs in GC has 
been reported in several studies [21–27]. The sensitivi-
ty of RT-PCR CTC detection was superior to the other 
less commonly used cytological detection methods 
involving fluorescence-activated cell sorting (FACS), 
immunohistochemistry (IHC), and immunocytochemi-
stry (ICC) [20]. For the identification of CTCs in GC, 
different markers and their combinations were tested 
in the analyzed studies. The combination of EpCAM, 
CK8, CK18, and CK19 seems to be prognostically 
the most relevant in GC [7, 24]. On the other side, 
single survivin expression also achieved prognostic 
significance in at least 2 studies [29, 30]. Based on the 
analyzed data, detection of CTCs might be used as 
a noninvasive method, not only for the confirmation 
of GC diagnosis, but also for estimation of prognosis.
Colorectal cancer (CRC)
In general, the detection of CTCs in colorectal cancer 
(CRC), independently of the method and markers 
274 Petra Eliasova et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0037
www.fhc.viamedica.pl
used, correlates with the stage of the cancer disease 
[31, 32]. On the other side, the correlation of CTCs 
with some known clinicopathological prognostic 
factors (e.g., T4 tumor size, perineural invasion, 
bowel obstruction, high preoperative CEA levels) 
is still uncertain [32]. It is believed that the correla-
tion of CTCs with clinicopathological factors would 
increase if the sensitivity of the CTC detection were 
higher. CTC positivity is observed in approximately 
40–50% of metastatic CRC patients. Differences in 
CTCs detection can be observed depending on the 
sampling site, as shown by Rahbari et al. [10], who 
tested compartmental differences of CTC in CRC. 
The qualitative and quantitative detection of CTCs 
was higher in the mesenteric venous blood (MVB) 
than in the central venous blood (CVB) of patients 
with CRC. It has been speculated that the liver works 
as a filter and stops CTCs from entering the central 
circulation [6]. Moreover, higher counts of CTCs were 
detected when the tumor was localized in the lower 
part of rectum than in the cases of middle and high 
rectal involvement [6, 33].
The biomarkers used for the CTCs detection 
in cytological or RT-PCR examination of patients 
with CRC are listed in Tables 3 and 4. Generally, 
the EpCAM pre-enrichment is a basis for further 
cytokeratine (CK19/20, CK8/18) and CEA testing. 
Recently, plastin3 has been shown to have significant 
clinical relevance. Plastin3 positivity in the PB was 
found to be associated with clinicopathological risk 
factors, such as depth of invasion, lymph node and 
liver metastasis, presence of peritoneal dissemination, 
increased recurrence rate, and higher Dukes stage. It 
is very important to note that plastin3 expression was 
also detected in all patients with recurrent disease, and 
at a level higher than in the case of prerecurrence and 
of patients without recurrence [34]. The correlation 
between CTCs and prognosis in CRCs was stronger 
if CKs and multiple markers were used than for the 
one-marker assay [35].
Recently, several meta-analyses evaluating the 
prognostic value of CTC examination in CRC have 
been published. Rahbari et al. [36] included 36 stu-
dies and 3094 patients in their final meta-analysis. 
The pooled analyses combining all sampling sites 
(PB, mesenteric PB (MPB), and BM) associated the 
detection of CTCs/DTCs with poor recurrence-free 
survival (RFS). Stratification by sampling site showed 
that detection of CTCs in the PB compartment was 
a statistically significant prognostic factor, but that 
detection in the MPB or BM was not. 
Similarly, 12 studies representing 1329 patients 
were suitable for pooled analysis of CRC patients in 
a prognostic study [37]. The OS and PFS were worse 
in CTC-positive patients, whereas analyzing PFS se-
parately, the subgroup with significantly worse survival 
rate contained over 35% CTC-positive patients. Mul-
tivariate analysis was performed on eight studies and 
identified the detection of CTCs as an independent 
prognostic factor for survival. Moreover, the meta-a-
nalysis reported that the detection of CTCs in PB of 
patients with resectable colorectal liver metastases, 
or with widespread metastatic CRC, was associated 
with disease progression and poor survival [37]. The 
study of Katsuno et al. [38] highlights the potential 
importance of cancer cell detection in the venous 
drainage of colorectal cancers as a prognostic marker 
and a mode of staging in this neoplastic disease.
Regarding the effect of chemotherapy on CTC 
counts, it has been evaluated that the prognosis of 
patients with undetectable CTCs after chemotherapy 
was significantly better [39]. Additionally, molecular 
detection of persistent postoperative CTCs has been 
confirmed as a prognostic marker of early relapse in 
I–III stage CRC patients, which could help to select 
patients for an enhanced follow-up and therapeutic 
program [40, 41].
In summary, it is expected that CTCs and DTCs 
will be used for mutational analysis of the genes con-
nected directly to the targeted therapy (e.g., KRAS, 
BRAF). The heterogeneity of the genetic profiles of 
cells from the primary tumor, metastatic tumors, and 
CTCs may be an explanation for the variable response 
to EGFR-inhibitor chemotherapy [5, 42, 43]. CTCs 
are not only a marker for advanced disease, but also 
have prognostic and predictive potential. A decrease 
in CTC levels during chemotherapy is correlated with 
improved responses to chemotherapy [39]. 
Several very important questions need to be an-
swered, and further studies are required to unify the 
isolation techniques before CTCs can be adapted 
for widespread clinical use. In particular, the follo-
wing questions should be central to future research: 
Can CTCs be used to deﬁne a group of patients with 
“resectable” metastases who should not undergo re-
section? Can CTCs be used to monitor the immediate 
effectiveness of systemic chemotherapy or to predict 
which chemotherapy would be most effective? Can 
CTCs be used to help staging patients with metastatic 
CRCs?
Finally, we are reminded that stage IV of colorec-
tal cancer is a disease with many possible outcomes, 
ranging from rapid death to recovery [40]. We also 
recall that our ability to predict which patient will 
experience which outcome is relatively limited. The 
detection of CTCs is a potentially promising biomar-
ker that could contribute to the staging of the cancer 
and this deserves a prospective study. 
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Conclusion
In summary, it is essential to establish sensitive, 
specific technologies to detect CTCs. More detailed 
analyses of their molecular characteristics should be 
performed with the aim of understanding the biology 
of CTCs and DTCs. This may provide a yet-untapped 
option to develop therapeutic strategies that will 
effectively treat and prevent metastatic process for 
each person individually. 
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